Yee Ju Visit 1: A 62-year-old woman presenting with dyspnea and cough

Managing NSCLC in elderly patients
0.75 AMA PRA Category 1 Credit(s)™
Launch Date:
May 07, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Paul A. Bunn, Jr., MD

Paul A. Bunn, Jr., MD
Professor, Medicine and Cancer Center
University of Colorado School of Medicine;
Professor, Cancer Center
University of Colorado Hospital
Executive Director, International Association for the Study of Lung Cancer
Aurora, CO

Dr. Bunn is the James Dudley endowed Professor of Lung Cancer research at the University of Colorado Cancer Center and School of Medicine. Dr. Bunn has been the principal investigator on the University of Colorado Lung Cancer SPORE since its inception. Dr. Bunn and his laboratory have studied the role of growth factor signaling in lung cancer, since he moved to the University of Colorado in 1984. Over this period, he has been involved in clinical trials of novel therapies and biomarkers for lung cancer. Dr. Bunn has mentored many fellows and young faculty who continue in lung cancer careers. Dr. Bunn will devote sufficient time to the SPORE to ensure its success. This effort will include 10% effort for administration and 20% effort for Project 2. As PI, Dr. Bunn chairs the Executive committee which meets monthly and the External and Internal advisory committees that meeting annually. He will set the agenda for the meetings. Dr. Bunn will lead the administration core and all of its functions. Dr. Bunn chairs the Developmental Research program and the Developmental Research committee. Dr. Bunn serves on the tissue use committee. Dr. Bunn is responsible for all reports, compliance issues, and for making final decisions on projects, cores, fiscal issues, etc. He is responsible for fund-raising and for interactions with the University including Dean's office, Cancer Center, and CTSA. In project 2, Dr. Bunn's laboratory is involved in the preclinical studies of EGFR inhibitors combined with FGFR, tankyrase and casein kinase II inhibitors as well as biomarkers for outcomes in these studies. Dr. Bunn works with Dr. Doebele in the design conduct and analyses of the proposed phase I trials.

David S. Ettinger, MD, FACP, FCCP

David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology
The John Hopkins University School of Medicine
Active Staff, Department of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

David S. Ettinger, MD, is the Alex Grass Professor of Oncology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He is also a professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences.
Dr. Ettinger received his medical degree from the University of Louisville, School of Medicine. He completed his medical internship and residency at the Albany Medical Center and Mayo Clinic, respectively. Dr. Ettinger completed his training in medical oncology at Johns Hopkins in 1975, and since then has been on the faculty of the School of Medicine. He was chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group (1980 to1982) and from 1990-2010, he was chairman of the Medical Oncology Lung Subcommittee of the Radiation Therapy Oncology Group. 
Dr. Ettinger is a member of the board of directors of the National Comprehensive Cancer Network (NCCN) as well as a member of the NCCN Guidelines Steering Committee. In addition, he has been chairman of the NCCN non–small cell lung cancer practice guidelines panel, antiemetic practice guidelines panel, and occult primary tumor practice guidelines panel. From 1982 through 1990, he was principal investigator of the phase I studies of new anticancer agents, sponsored by the National Institutes of Health. Dr. Ettinger's research interests are in new drug development and innovative multidisciplinary treatment strategies in lung cancer and sarcomas. He is also interested in improving supportive care measures associated with cancer and its treatment. Dr. Ettinger has authored or co-authored over 200 articles and serves as an editor for Current Treatment Options in Oncology. He has edited 3 books:  Thoracic Oncology, Kluwer Academic Publishers, 2001; Current Cancer Therapeutics, 5th Edition, Springer, 2009; and Supportive Care in Cancer Therapy, Humana Press, 2009.
Dr. Ettinger is a former president of the Maryland Division of the American Cancer Society. In 1997, he received the American Cancer Society's highest national divisional award, the St. George Medal.

Mark A. Socinski, MD

Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section, Division of Hematology Oncology
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh, UPMC Cancer Pavilion
Pittsburgh, PA

Mark A. Socinski, MD, is Professor of Medicine and Thoracic Surgery and Director of the Lung Cancer Section, Division of Hematology/Oncology at the University of Pittsburgh. He also is Co-Director of the UPMC Lung Cancer Center of Excellence and the Lung and Thoracic Malignancies Program and the Clinical Associate Director of the Specialized Program of Research Excellence (SPORE) in Lung Cancer at the University of Pittsburgh Medical Center. He is board certified in internal medicine and medical oncology.
Dr. Socinski received his MS in pathology and his MD from the University of Vermont in Burlington. He completed an internal medicine internship and residency at Harvard Medical School Beth Israel Hospital in Boston. He went on to complete medical oncology and clinical medicine fellowships at the Dana-Farber Cancer Institute, Harvard Medical School.
Dr. Socinski is a member of several professional organizations including the American College of Physicians, the American Society of Clinical Oncology, Cancer and Leukemia Group B, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He has authored many manuscripts principally in the field of Thoracic Oncology.
1. Identify potential surrogate endpoints in order to improve evaluation of patients with NSCLC
2. Incorporate patients' questions and concerns regarding maintenance therapy when developing treatment plans in order to better address their individual needs
3. Identify elderly patients with NSCLC who would benefit from maintenance therapy in order to improve progression-free survival